Objectives: To estimate the budget impact of the introduction of biosimilar infliximab for the treatment of Crohn's disease (CD) in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia.
Methods: A 3-year, prevalence-based budget impact analysis for biosimilar infliximab to treat CD was developed from third-party payers' perspective. The model included various scenarios depending on whether interchanging originator infliximab with biosimilar infliximab was allowed or not.
Results: Total cost savings achieved in biosimilar scenario 1 (interchanging not allowed) and BSc2 (interchanging allowed in 80% of the patients) were estimated to €8.0 million and €16.9 million in the six countries. Budget savings may cover the biosimilar infliximab therapy for 722-1530 additional CD patients.
Conclusions: Introduction of biosimilar infliximab to treat CD may offset the inequity in access to biological therapy for CD between Central and Eastern European countries.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737167.2015.1067142 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities.
Expert Opin Biol Ther
January 2025
Department of Pediatric Rheumatology, Kocaeli University, Kocaeli, Turkey.
Article Synopsis
- Biosimilars are biologic drugs that mimic established medications for treating rheumatic diseases and become available as cost-effective alternatives once original patents expire.
- Since their introduction in pediatric rheumatology in 2013, several biosimilars have been launched, offering more treatment options for children with conditions like juvenile idiopathic arthritis.
- The article emphasizes the need for education and effective communication among healthcare providers and patients to enhance understanding and ensure proper use of biosimilars.
Impact of Nonmedical Switches From Reference Infliximab to Biosimilars on Disease Control Within a Rheumatology Practice.
J Pharm Technol
December 2024
Department of Medicine, Larner College of Medicine, The University of Vermont, Burlington, VT, USA.
Infliximab is an anti-tumor necrosis factor agent used to treat rheumatologic disease. Evidence on the safety of switching to biosimilars and the associated risk factors for flares/loss of disease control within rheumatology is limited. The primary objective is to evaluate nonmedical switches from reference infliximab to biosimilars in rheumatology on risks and level of disease control.
View Article and Find Full Text PDFAssessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China.
Front Public Health
December 2024
Vanke School of Public Health, Tsinghua University, Beijing, China.
Background: As China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern. Biosimilars, potentially lower-cost versions of biologics, may improve access to more affordable yet comparably effective treatments. Encouragingly, China launched its abbreviated biosimilar pathway in 2015, and since then, a large number of biosimilars have been approved.
View Article and Find Full Text PDFAseptic abscess syndrome: a case report of a patient achieving remission with both infliximab originator and biosimilar administered at varied intervals.
Front Immunol
December 2024
Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Rheumatology Unit, Sapienza University of Rome, Rome, Italy.
Aseptic abscesses syndrome is a rare but increasingly recognized disease that falls within the spectrum of autoinflammatory disorders. Here, we describe the case of a patient who presented with abdominal pain and fever, along with multiple abdominal and extra-abdominal abscesses, in the absence of underlying hematologic, autoimmune, infectious, or neoplastic conditions. Initially, the patient responded to glucocorticoids, but experienced several flares upon discontinuation, leading to the initiation of treatment with a TNFα inhibitor.
View Article and Find Full Text PDFEfficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis.
J Clin Med
November 2024
Division of Rheumatology, School of Medicine, Dokuz Eylul University, 35220 Izmir, Turkey.
CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!